Ocugen, Inc.
Bioscience Park Center
12635 E Montview Boulevard
Aurora
Colorado
80045
United States
Tel: 720-859-3549
Website: http://ocugen.com/
243 articles about Ocugen, Inc.
-
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
5/24/2022
Ocugen, Inc. today announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart® (autologous chondrocyte-derived neocartilage).
-
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
5/23/2022
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright Global Investment Conference, on May 24, 2022, at 1:30pm ET in Miami Beach, Florida.
-
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)Dosing to Resume Immediately
5/23/2022
Ocugen, Inc. announced that the U.S. Food and Drug Administration lifted the clinical hold on the Company’s Phase 2/3 clinical trial, OCU-002, for COVAXIN™.
-
Lifting the clinical hold will allow Ocugen to continue to assess the vaccine in its ongoing study and potentially support its efforts to achieve EUA or full approval.
-
Ocugen Provides Business Update and First Quarter 2022 Financial Results
5/6/2022
Ocugen, Inc. reported first quarter 2022 financial results along with a general business update.
-
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
5/2/2022
Ocugen, Inc. today announced that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results at 8:30 a.m. ET on Friday, May 6, 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
4/29/2022
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology’s (ARVO) 2022 Annual Meeting.
-
The DSMB for Ocugen's Phase I/II trial of OCU400, a gene therapy in development for Retinitis Pigmentosa (RP), recommended the study proceed with enrolling more patients.
-
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
4/25/2022
Ocugen, Inc. announced today that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400 reviewed safety data based on dosing to date and recommended that the study proceed with enrolling additional subjects.
-
Ocugen, Inc. to Present at NobleCon18
4/19/2022
Ocugen, Inc. announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will present on-location at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference.
-
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
-
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
4/18/2022
Ocugen, Inc. today announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive territory to include commercialization of COVAXIN™ in Mexico.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
4/12/2022
Ocugen, Inc. announced that the Company was informed by the U.S. Food and Drug Administration (FDA) that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ (BBV152), OCU-002, on clinical hold.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
4/1/2022
Ocugen, Inc. announced that the first patient has been dosed in the Phase 1/2 clinical trial of OCU400.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
3/23/2022
Ocugen, Inc. today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022.
-
Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance
3/21/2022
Ocugen, Inc. today announced the appointment of Jessica Crespo, CPA, as Chief Accounting Officer and Senior Vice President, Finance.